Development of AX-5006, a Small Molecule Inhibitor of CsgA Aggregation as a Symptomatic & Disease-Modifying Treatment for Parkinson’s Disease
Time: 1:45 pm
day: Day Two Track A (PM)
Details:
- Understanding the role of the microbiome in Parkinson’s Disease
- Outlining the rationale for targeting CsgA as a therapeutic for Parkinson’s Disease
- Revealing the preclinical efficacy and development profile of AX-5006
